TABLE 1.
Baseline Characteristics (326 Hepatectomies)
| Characteristic | Overall 2016–2019, n = 326 | Period 2016–2017, n = 138 (42%) | Period 2018–2019, n = 188 (58%) | P |
|---|---|---|---|---|
| Patients | ||||
| Sex, male | 156 (47.9) | 66 (47.8) | 90 (47.9) | 0.99 |
| Age, y | 60 ± 13 | 60 ± 12 | 60 ± 14 | 0.99 |
| Age ≥ 75 y | 37 (11.3) | 11 (7.9) | 26 13.8) | 0.09 |
| ASA score ≥ III | 100 (30.7) | 23 (16.7) | 77 (41.0) | <0.0001 |
| Cirrhosis | 28 (8.6) | 7 (5.1) | 21 (11.2) | 0.052 |
| Tumors | ||||
| Malignant | 298 (91.4) | 129 (93.5) | 169 (89.9) | 0.25 |
| Primary | ||||
| Hepatocellular carcinoma | 35 (10.7) | 8 (5.8) | 27 (14.4) | 0.01 |
| Intrahepatic cholangiocarcinoma | 11 (3.4) | 5 (3.6) | 6 (3.2) | 0.83 |
| Perihilar cholangiocarcinoma | 11 (3.4) | 3 (2.2) | 8 (4.3) | 0.30 |
| Gallbladder carcinoma | 6 (1.8) | 2 (1.4) | 4 (2.1) | 0.65 |
| Other* | 3 (0.9) | 1 (0.7) | 2 (1.1) | 0.75 |
| Secondary | ||||
| CRM | 214 (65.6) | 106 (76.8) | 108 (57.4) | 0.0003 |
| NEM | 4 (1.2) | 0 (—) | 4 (2.1) | 0.08 |
| NCNNE | 14 (4.3) | 4 (2.9) | 10 (5.3) | 0.29 |
| Liver and renal function tests | ||||
| Bilirubin µmol/L | 12 ± 20 | 9 ± 6 | 14 ± 25 | 0.03 |
| Bilirubin > 34 µmol/L | 10 (3.1) | 2 (1.4) | 8 (4.3) | 0.10 |
| AST, IU/L | 38 ± 46 | 32 ± 23 | 43 ± 56 | 0.05 |
| Albumin, g/L | 42 ± 22 | 41 ± 3 | 42 ± 28 | 0.63 |
| ALBI score > −2.6 (high risk) | 100 (31) | 36 (26) | 64 (34) | 0.12 |
| Prothrombin level, % of normal | 94 ± 21 | 93 ± 24 | 94 ± 19 | 0.96 |
| Creatinine, µmol/L | 88 ± 282 | 70 ± 26 | 97 ± 369 | 0.35 |
| Creatinine > 117 µmol/L | 13 (3.9) | 3 (2.2) | 10 (5.3) | 0.15 |
Qualitative variables are given as number (%); continuous variables are given as mean ± SD.
*
Cystadenocarcinoma (1 case) and primary sarcoma of the liver (2 cases).
ALBI, Albumin-Bilirubin; ASA, American Society of Anaesthesiology; AST, aspartate aminotransferase; CRM, colorectal metastases; NCNNE, noncolorectal non neuroendocrine metastases; NEM, neuroendocrine metastases.